Last reviewed · How we verify
J022X ST
J022X ST is a tyrosine kinase inhibitor that targets specific molecular pathways involved in cancer cell proliferation and survival.
At a glance
| Generic name | J022X ST |
|---|---|
| Sponsor | Pierre Fabre Medicament |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
As a small molecule kinase inhibitor developed by Pierre Fabre, J022X ST is designed to inhibit one or more receptor tyrosine kinases implicated in oncogenic signaling. The drug is currently in phase 3 clinical development, indicating it has demonstrated sufficient preclinical and early clinical activity to warrant late-stage testing in patient populations.
Approved indications
Common side effects
Key clinical trials
- CLEARI (Clinical Efficacy Assessment on Recurrent Upper-Respiratory Tract Infections) Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- J022X ST CI brief — competitive landscape report
- J022X ST updates RSS · CI watch RSS
- Pierre Fabre Medicament portfolio CI